NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 9, 2013, Pages 665-673

  Zhu, Wenjie ^a   Fu, Weijiang ^a   Hu, Likuan ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

mTOR; NVP BEZ235; PI3K; prostate cancer; radiosensitivity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IONIZING RADIATION; M PHASE CELL CYCLE CHECKPOINT; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; QUINOLINES; RADIATION TOLERANCE; RADIATION, IONIZING; RADIOPHARMACEUTICALS; RECEPTORS, ANDROGEN; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84885583248     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1443     Document Type: Article

References (34)

1. Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010;70:2141.
2. Ihle NT, Powis G. Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy. Mol Cancer Ther 2009;8:1.
3. Park CM, Park MJ, Kwak HJ, et al. Ionizing radiation enhances Matrix Metalloproteinase-2 secretion and invasion of glioma cells through Src/Epidermal Growth Factor Receptor-mediated p38/Akt and Phosphatidylinositol 3-Kinase/Akt signaling pathways. Cancer Res 2006;66:8511.
4. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: Inside-out and outside-in. Mol Cancer Ther 2007;6:789.
5. Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol 2009;4:127.
6. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075.
7. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851.
8. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628.
9. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidy-linositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidy-linositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221.
10. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 2009;4:43.
11. Rashid A, Liu CQ, Sanli T, et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol 2011;6:144.
12. Contessa JN, Hampton J, Lammering G. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002;21:4032.
13. Zhan M, Han ZC. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 2004;19:915.
14. Leith JT. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate 1994;24:119.
15. Leith JT, Cook S, Chougule P, et al. Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: Comparative cellular radiosensitivity and hypoxic percentages. Acta Neurochir Suppl 1994;62:18.
16. Ezekwudo D, Shashidharamurthy R, Devineni D, et al. Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett 2008;270:277.
17. Akagunduz O, Karaca B, Atmaca H, et al. Radiosensitization of hormone-refractory prostate cancer cells by gossypol treatment. J BUON 2010;15:763.
18. Boothman DA, Greer S, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human car-cinoma cells by h-lapachone (3,4-dihydro-2,2- dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 1987;47:5361.
19. Peterson SR, Kurimasa A, Oshimura M, et al. Loss of the catalytic subunit of the DNA-dependent protein kinase in DNA double-strand-break-repair mutant mammalian cells. Proc Natl Acad Sci USA 1995;92:3171.
20. McKenna WG, Muschel RJ, Gupta AK, et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866.
21. Prevo R, Deutsch E, Sampson O, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008;68:5915.
22. Cengel KA, Voong KR, Chandrasekaran S, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007;9:341.
23. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-RAS. Cancer Res 2005;65:3226.
24. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev 2006;6:729.
25. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065.
26. Heinlein CA, Chang CS. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276.
27. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012;24:251.
28. Carver BS, Chapinski C, Wongvipat J. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19: 575.
29. Kaarbø M, Mikkelsen OL, Malerød L, et al. PI3K-AKTmTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 2010;32:11.
30. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022.
31. Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26:611.
32. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606.
33. Mukherjee B, Tomimatsu N, Amancherla K, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia 2012;14:34.
34. Konstantinidou G, Bey EA, Rabellino A, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of Non-Small Cell Lung Cancer harboring K-RAS mutations. Cancer Res 2009;69:7644.